Valbiotis
Develops clinically proven, plant-based supplements for metabolic diseases.
ALVAL | PA
Overview
Corporate Details
- ISIN(s):
- FR0013254851
- LEI:
- 969500VP4JBJCF0MOP60
- Country:
- France
- Address:
- RUE PAUL VATINE, 17180 PERIGNY
- Website:
- https://www.valbiotis.com/en/
- Sector:
- Manufacturing
- Industry:
- Manufacture of other food products
Description
Valbiotis is a research and development company that develops and commercializes plant-based dietary supplements for the prevention and management of metabolic diseases. The company's portfolio is centered on its patented "TOTUM" line of active substances, which undergo rigorous clinical trials to validate their efficacy. Key products include TOTUM•63 for reducing blood glucose in prediabetic individuals, TOTUM•448 for cardio-liver health, and TOTUM•854 for managing blood pressure. Valbiotis provides scientifically proven, natural, non-drug solutions and is transitioning from a research-focused model to a commercial-stage enterprise.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-11 20:00 |
Valbiotis announces that it has received Food and Drug Administration (FDA) app…
|
English | 490.1 KB | ||
| 2023-12-04 17:40 |
VALBIOTIS SA:
|
English | 109.2 KB | ||
| 2023-12-04 17:40 |
Valbiotis : Déclaration mensuelle du nombre d’actions et droits de vote – Novem…
|
French | 109.2 KB | ||
| 2023-11-07 17:40 |
Valbiotis announces the success of the TOTUM•63 mode of action clinical study,…
|
English | 680.6 KB | ||
| 2023-11-07 17:40 |
Valbiotis annonce le succès de l’étude clinique de mode d’action sur TOTUM•63, …
|
French | 684.9 KB | ||
| 2023-11-06 17:40 |
Valbiotis : Déclaration mensuelle du nombre d’actions et droits de vote – Octob…
|
French | 108.9 KB | ||
| 2023-10-04 17:40 |
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
|
French | 109.3 KB | ||
| 2023-10-02 17:40 |
VALBIOTIS SA: the Phase II/III REVERSE-IT study selected for an oral presentati…
|
English | 456.2 KB | ||
| 2023-10-02 17:40 |
VALBIOTIS SA : l’étude de Phase II/III REVERSE-IT sélectionnée pour une présent…
|
French | 459.5 KB | ||
| 2023-09-28 17:40 |
Valbiotis publishes its financial report for the first half of 2023 and confirm…
|
English | 933.0 KB | ||
| 2023-09-28 17:40 |
Valbiotis publie son rapport financier pour le premier semestre 2023 et confirm…
|
French | 862.4 KB | ||
| 2023-09-28 17:40 |
Valbiotis : Rapport semestriel 2023
|
French | 3.8 MB | ||
| 2023-09-11 17:40 |
VALBIOTIS SA: Valbiotis presents the full results of the Phase II/III REVERSE-I…
|
English | 1.1 MB | ||
| 2023-09-11 17:40 |
VALBIOTIS SA: Valbiotis présente les résultats complets de l’étude de Phase II/…
|
French | 1.2 MB | ||
| 2023-09-06 17:40 |
VALBIOTIS SA: Information mensuelle relative au nombre total de droits de vote …
|
French | 109.0 KB |
Automate Your Workflow. Get a real-time feed of all Valbiotis filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Valbiotis
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Valbiotis via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-01-17 | N/A | Other | Other | 10,400 | 46,072.00 EUR |
Peer Companies
